Aduro Biotech Europe, a subsidiary of U.S.-based Aduro Biotech, is focused on the development of B-select monoclonal antibodies (mAB) for the treatment of cancer and other serious conditions. The lead B-select program is BION-1301, an anti-APRIL antibody expected to enter clinical development for the treatment of multiple myeloma in late 2017.
The B-select technology is a key component of Aduro’s ’ development pipeline, which also consists of LADD (live, attenuated double-deleted Listeria monocytogenes) and STING Pathway Activators. Collectively, Aduro’s three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth. To learn more, visit www.aduro.com.
Area of work
Oncology, Immunology, Antibodies, Drug development
Drug development Pipeline
Target discovery – Clinical development
``Here are facilities that are not available anywhere else. The Pivot Park Screening Centre (PPSC) is a good example of this. PPSC has a collection of more than 300,000 compounds that can serve as a starting point for new medicines. Here, as a life science entrepreneur, you can have your target screened and have your own new compounds tested. ``